Published in Cancer Weekly, June 23rd, 2009
"Repeat right lobar radioembolization with supratherapeutic activity of (90)y caused shrinking of the tumors and the right lobe with no adverse outcome. With an adequate tumor-free future liver remnant, one hepatic lobe bearing a large tumor burden may be administered supratherapeutic activity of Y-90, risking lobar ablation for greater probability of tumor eradication. This is analogous to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.